Prosecution Insights
Last updated: October 02, 2026

Examiner: HENLEY III, RAYMOND J

Tech Center 1600 • Art Units: 1614 1629 1652

This examiner grants 84% of resolved cases

Analysis

Raymond J. Henley III is an experienced examiner in Art Unit 1614, part of Tech Center 1600. With 1258 resolved cases, his profile offers a very robust data set for analysis. He maintains a high allowance rate of 83.5 percent. This suggests that he is very open to finding allowable subject matter, making him a favorable examiner for applicants. The 1258 resolved cases establish a reliable baseline for predicting outcomes in Art Unit 1614.

The interview lift for this examiner is a modest 2.3 percent. Given that his baseline allowance rate is already 83.5 percent, the small lift suggests that interviews have a minimal impact on the overall probability of success. While an interview may still be useful for clarifying specific points, it is not as critical a tool as it is with other examiners. Practitioners can feel confident in the high baseline success rate even without an interview in Tech Center 1600.

In terms of efficiency, the median days to allowance is 693. This is an impressively fast timeline, indicating a very streamlined prosecution process. The combination of an 83.5 percent allowance rate and a 693-day median pendency makes for an ideal prosecution experience. Applicants can use these metrics from his 1258 resolved cases to set very positive expectations for their own applications. The 693-day duration is a key benchmark for efficiency.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

83.5%
Allow Rate
+23.5% vs TC avg
1,313
Total Applications
+2.3%
Interview Lift
693
Avg Prosecution Days
Based on 1258 resolved cases, 2023–2026

Rejection Statute Breakdown

5.9%
§101 Eligibility
8.6%
§102 Novelty
21.4%
§103 Obviousness
31.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19572691 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19572667 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19569963 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Final Rejection Veradermics, Incorporated
19570012 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19569918 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Final Rejection Veradermics, Incorporated
19546276 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19542655 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19539689 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19538689 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19538745 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19444686 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19443936 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19442911 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19442899 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19442979 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19442974 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19441484 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19436869 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19430093 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19420555 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19402812 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19329494 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Final Rejection Veradermics, Incorporated
19329476 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Final Rejection Veradermics, Incorporated
19328077 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Final Rejection Veradermics, Incorporated
19308124 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Final Rejection Veradermics, Incorporated
19267447 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19267464 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19260035 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19258817 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19253703 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Final Rejection Veradermics, Incorporated

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month